Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir ▼ Plus Sofosbuvir ▼ in Genotype 1 HCV Patients With and Without Cirrhosis

Press/Media: Press / Media

PeriodApr 24 2015

Media coverage

1

Media coverage

  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir ▼ Plus Sofosbuvir ▼ in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletIbero News
    CountrySpain
    Date4/24/15
    PersonsEric J Lawitz